Key facts
- It has raised $14.0M; the latest was Early Stage VC ($14.0M) in Sep 2025.
- Notable investors include Zheshang Venture Capital, Lotus Lake Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Yuannang Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Yuannang Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Yuannang Biotechnology
Developer of musculoskeletal regenerative medical materials designed for clinical applications. The company offers integrated drug pipelines, clinical trial data, and therapeutic insights, enabling pharmaceutical researchers and healthcare innovators to accelerate development and improve treatment efficacy.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2022
- Ownership
- Privately Held (backing)
Yuannang Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Yuannang Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Yuannang Biotechnology in its N-PORT filings yet. We sweep new filings monthly.